<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lidocaine (local and regional anesthetic) and (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lidocaine (local and regional anesthetic) and (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lidocaine (local and regional anesthetic) and (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12241" href="/d/html/12241.html" rel="external">see "Lidocaine (local and regional anesthetic) and (systemic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="16016" href="/d/html/16016.html" rel="external">see "Lidocaine (local and regional anesthetic) and (systemic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F24520860"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lidomark 1/5 [DSC];</li>
<li>Lidomark 2/5 [DSC];</li>
<li>P-Care X [DSC];</li>
<li>ReadySharp Lidocaine [DSC];</li>
<li>Xylocaine;</li>
<li>Xylocaine-MPF</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869226"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Xylocaine;</li>
<li>Xylocaine Plain;</li>
<li>Xylocard</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F8768603"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiarrhythmic Agent, Class Ib;</li>
<li>
                        Local Anesthetic</li></ul></div>
<div class="block doa drugH1Div" id="F8768809"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6fef1f7c-57c6-4226-b257-b8b6de839621">Interstitial cystitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Interstitial cystitis (bladder pain syndrome) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Various dosage regimens of alkalinized lidocaine alone or with heparin (20,000 to 50,000 units) have been used. When lidocaine and heparin are mixed, there is a risk of precipitation if proper alkalinization does not occur. Prior to administration, lidocaine stability and pH should be determined after the components have been mixed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22082303']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22082303'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intravesicular: </b>Single instillation: Single bladder installation of lidocaine (200 mg)/heparin (50,000 units)/sodium bicarbonate (420 mg) in 15 mL of sterile water, instilled into the bladder via catheter and allowed to dwell for 30 minutes before drainage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22082303']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22082303'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intravesicular: </b>Weekly instillation: Weekly bladder instillations for 12 consecutive weeks with lidocaine 4% (5 mL [200 mg])/heparin (20,000 units)/sodium bicarbonate 7% (25 mL [1,750 mg]), instilled into an empty bladder via catheter and allowed to dwell for 30 minutes before drainage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23432185']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23432185'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intravesicular: </b>Daily instillation: Daily bladder instillations for 5 days with lidocaine (200 mg)/sodium bicarbonate 8.4% solution (final volume of 10 mL), instilled into an empty bladder and allowed to dwell for 1 hour before drainage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19021619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19021619'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="60043faa-1c30-4e2e-81e8-9b739ec623d7">Intraosseous, infusion pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraosseous, infusion pain (off-label use):</b>
<b>Note:</b> May consider in a conscious patient to decrease pain prior to the infusion of fluid, medications, or blood products through the intraosseous cannula (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22029625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22029625'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Lidocaine 2% preservative-free: <b>Intraosseous:</b> Initial dose: 20 or 40 mg over 1 to 2 minutes; may administer 1 or 2 additional doses of 20 mg; follow each dose with an NS flush; maximum total dose not established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20868946','lexi-content-ref-22029625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20868946','lexi-content-ref-22029625'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46dd0d85-641f-4236-9e10-1bfcf6c0833a">Local or regional anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Local or regional anesthesia:</b>
<b> Note: </b>Dosage varies with procedure, degree of anesthesia needed, vascularity of tissue, duration of anesthesia required, and physical condition of patient. General maximum single dose (unless noted otherwise below): 4.5 mg/kg/dose not to exceed 300 mg. Refer to institutional protocols; doses presented below are examples of recommended volumes and concentrations. Use the lowest concentration and smallest dose to achieve desired result; avoid rapid administration; inject slowly in fractional doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Caudal:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> The maximum recommended dose should not be administered at intervals of &lt;90 minutes. A test dose such as 2 to 3 mL of lidocaine 1.5% should be administered at least 5 minutes prior to injecting the total volume of lidocaine required for a caudal epidural block. The test dose should be repeated if the patient is moved in a manner that may have displaced the catheter. Epinephrine, if contained in the test dose, may serve as a warning of unintentional intravascular injection.</p>
<p style="text-indent:-2em;margin-left:6em;">Obstetrical <b>analgesia</b> (preservative free):</p>
<p style="text-indent:-2em;margin-left:8em;">Lidocaine 1%: 20 to 30 <b>mL</b>; total dose: 200 to 300 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">Lidocaine 5%: Vaginal delivery: 1 <b>mL</b>; total dose: 50 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">Lidocaine 5%: Caesarean delivery: 1.5 <b>mL</b>; total dose: 75 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Surgical <b>anesthesia</b> (preservative free):</p>
<p style="text-indent:-2em;margin-left:8em;">Lidocaine 1.5%: 15 to 20 <b>mL</b>; total dose: 225 to 300 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">Lidocaine 5%: 1.5 to 2 <b>mL</b>; total dose: 75 to 100 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Epidural:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Dosage varies with the number of dermatomes to be anesthetized (generally 2 to 3 mL of the indicated concentration per dermatome). The maximum recommended dose should not be administered at intervals of &lt;90 minutes. A test dose, such as 2 to 3 mL of lidocaine 1.5%, should be administered at least 5 minutes prior to injecting the total volume of lidocaine required for a lumbar epidural block. The test dose should be repeated if the patient is moved in a manner that may have displaced the catheter. Epinephrine, if contained in the test dose, may serve as a warning of unintentional intravascular injection.</p>
<p style="text-indent:-2em;margin-left:6em;">Thoracic epidural anesthesia (preservative free): Lidocaine 1%: 20 to 30 <b>mL</b>; total dose: 200 to 300 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Lumbar epidural <b>anesthesia</b> (preservative free):</p>
<p style="text-indent:-2em;margin-left:10em;">Lidocaine 1.5%: 15 to 20 <b>mL</b>; total dose: 225 to 300 mg.</p>
<p style="text-indent:-2em;margin-left:10em;">Lidocaine 2%: 10 to 15 <b>mL</b>; total dose: 200 to 300 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">Lumbar epidural <b>analgesia</b> (preservative free): Lidocaine 1%: 25 to 30 <b>mL</b>; total dose: 250 to 300 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Infiltration:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Percutaneous: Lidocaine 0.5% or 1%: 1 to 60 mL; total dose: 5 to 300 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">IV regional: Lidocaine 0.5%: 10 to 60 mL; total dose: 50 to 300 mg; maximum dose: 4 mg/kg/dose. <b>Note:</b> Only the 50 mL, single-dose vial containing lidocaine hydrochloride 0.5% injection should be used for IV regional anesthesia.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Nerve block, peripheral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Brachial: Lidocaine 1.5%: 15 to 20 <b>mL</b>; total dose: 225 to 300 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Dental: Lidocaine 2%: 1 to 5 <b>mL</b>; total dose: 20 to 100 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Intercostal: Lidocaine 1%: 3 <b>mL</b>; total dose: 30 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Paravertebral: Lidocaine 1%: 3 to 5 <b>mL</b>; total dose: 30 to 50 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Pudendal (each side): Lidocaine 1%: 10 <b>mL</b>; total dose: 100 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Nerve block, sympathetic:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Cervical: Lidocaine 1%: 5 <b>mL</b>; total dose: 50 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Lumbar: Lidocaine 1%: 5 to 10 <b>mL</b>; total dose: 50 to 100 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Paracervical:</b> Obstetrical analgesia (each side): Lidocaine 1%: 10 <b>mL</b>; total dose: 100 mg, wait 5 minutes before administering on other side; maximum dose: 200 mg (100 mg on each side) in a 90 minute period.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Retrobulbar:</b> Lidocaine 4%: 3 to 5 <b>mL</b>; total dose: 120 to 200 mg; a portion of this dose is injected retrobulbarly and the remainder may be used to block the facial nerve.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f42c553-e8c4-4b54-98fb-e270b999dc6b">Ventricular arrhythmias</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular arrhythmias:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Sudden</b>
<b> cardiac arrest due to ventricular fibrillation or pulseless ventricular tachycardia (unresponsive to CPR, defibrillation, epinephrine) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Bolus dose:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV/intraosseous:</b> 1 to 1.5 mg/kg; repeat with 0.5 to 0.75 mg/kg every 5 to 10 minutes as necessary; a typical dose is 50 to 100 mg; maximum cumulative dose: 3 mg/kg or up to 300 mg within 1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Endotracheal</b> (off-label route; only use when IV or intraosseous access cannot be established): 2 to 3.75 mg/kg; before administration dilute in 5 to 10 mL NS or sterile water. <b>Note:</b> Absorption is greater with sterile water and results in less impairment of PaO<sub>2</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous infusion: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Even if lidocaine was not administered during resuscitation but return of spontaneous circulation was achieved, may still consider a lidocaine infusion to prevent recurrent arrhythmia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33081529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33081529'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV/intraosseous</b>
<b>:</b> 1 to 4 mg/minute; if used beyond 24 hours, the rate of elimination can be prolonged and dose reduction may be necessary; monitor serum concentrations and signs or symptoms of toxicity to guide dose adjustment; maximum cumulative dose: 300 mg within 1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Ventricular tachycardia, hemodynamically stable, sustained monomorphic:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Bolus dose:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 1 to 1.5 mg/kg; repeat with 0.5 to 0.75 mg/kg every 5 to 10 minutes as necessary; a typical dose is 50 to 100 mg; maximum cumulative dose: 3 mg/kg or up to 300 mg within 1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous infusion: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Consider for use after bolus dose to prevent recurrent arrhythmia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 1 to 4 mg/minute; if used beyond 24 hours, the rate of elimination can be prolonged and dose reduction may be necessary; monitor serum concentrations and signs or symptoms of toxicity to guide dose adjustment; maximum cumulative dose: 300 mg within 1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991705"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Administer lower maintenance infusion rate with close monitoring for toxicity.</p></div>
<div class="block doha drugH1Div" id="F50989026"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Administer lower maintenance infusion rate with close monitoring for toxicity.</p></div>
<div class="block doe drugH1Div" id="F8768812"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F8768807"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16016" href="/d/html/16016.html" rel="external">see "Lidocaine (local and regional anesthetic) and (systemic): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1db5568a-b19e-410b-8e68-312f7999855b">Ventricular fibrillation or pulseless ventricular tachycardia, shock-refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT), shock-refractory:</b> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">IV, Intraosseous (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26473000','lexi-content-ref-30571264','lexi-content-ref-20956230','lexi-content-ref-33081526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26473000','lexi-content-ref-30571264','lexi-content-ref-20956230','lexi-content-ref-33081526'])">Ref</a></span>): Initial:</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: 1 mg/kg/dose; follow with continuous IV infusion; may administer second bolus if delay between initial bolus and start of infusion is &gt;15 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: 20 to 50 mcg/kg/minute. Per manufacturer, do not exceed 20 mcg/kg/minute in patients with shock, hepatic disease, cardiac arrest, or CHF.</p>
<p style="text-indent:-2em;margin-left:4em;">Endotracheal: Loading dose: 2 to 3 mg/kg/dose; flush with 5 mL of NS and follow with 5 assisted manual ventilations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3163bdc5-e962-4b25-b4f3-83ef806b1075">Anesthesia, local injectable</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anesthesia, local injectable:</b> Dose varies with procedure, degree of anesthesia needed, vascularity of tissue, duration of anesthesia required, and physical condition of patient.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cutaneous infiltration</i>: Children and Adolescents: Typically solutions with concentration &lt;2% should be used (allow for larger volumes); maximum dose: 5 mg/kg/dose not to exceed the recommended adult maximum dose of 300 mg/dose; do not repeat within 2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intraosseous line or infusion pain:</i> Infants, Children, and Adolescents: Lidocaine 1% or 2 % preservative-free solution: Intraosseous: Initial dose: 0.5 mg/kg over 1 to 2 minutes; usual adult dose range and maximum: 20 to 50 mg/dose; follow with NS flush; immediately following the NS flush, some centers administer a second lower (50% dose reduction) lidocaine dose over 30 to 60 seconds (usual adult maximum repeat dose: 20 mg/dose); if discomfort reoccurs, may repeat doses at a maximum frequency of every 45 minutes during intraosseous access; maximum total dose not established, some centers suggest that dose should not exceed: 3 mg/kg/24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19947861','lexi-content-ref-21345096','lexi-content-ref-20868946','lexi-content-ref-22029625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19947861','lexi-content-ref-21345096','lexi-content-ref-20868946','lexi-content-ref-22029625'])">Ref</a></span>). <b>Note:</b> Intraosseous access devices have a minimum weight and age for a particular device in addition to specific instruction for insertion and validation; consult product specific information for more detail.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51117800"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, accumulation of metabolites may be increased in renal dysfunction. Not dialyzable (0% to 5%) by hemo- or peritoneal dialysis; supplemental dose is not necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>)</p></div>
<div class="block dohp drugH1Div" id="F51117801"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children and Adolescents: Use with caution; reduce dose. Monitor lidocaine concentrations closely and adjust infusion rate as necessary; consider alternative therapy. Maximum rate of continuous IV infusion: 20 mcg/kg/minute</p></div>
<div class="block adr drugH1Div" id="F8768664"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Effects vary with route of administration. Many effects are dose-related.</p>
<p style="text-indent:0em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (positional headache following spinal anesthesia: 3%), shivering (following spinal anesthesia: 2%), radiculopathy (≤2%; transient pain; subarachnoid administration)</p>
<p style="text-indent:0em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, cardiac arrhythmia, circulatory shock, coronary artery vasospasm, edema, flushing, heart block, hypotension (including following spinal anesthesia), local thrombophlebitis, vascular insufficiency (periarticular injections)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Agitation, anxiety, apprehension, cauda equina syndrome (following spinal anesthesia), coma, confusion, disorientation, dizziness, drowsiness, euphoria, hallucination, hyperesthesia, hypoesthesia, intolerance to temperature, lethargy, loss of consciousness, metallic taste, nervousness, paresthesia, peripheral neuropathy (following spinal anesthesia), psychosis, seizure, slurred speech, twitching</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (including following spinal anesthesia), vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactoid reaction, anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor, weakness</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, dyspnea, respiratory depression, respiratory insufficiency (following spinal anesthesia)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Asystole, dermatological reaction, diplopia (following spinal anesthesia), methemoglobinemia</p></div>
<div class="block coi drugH1Div" id="F8768645"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to lidocaine or any component of the formulation; hypersensitivity to another local anesthetic of the amide type; Adam-Stokes syndrome; Wolff-Parkinson-White syndrome; severe degrees of SA, AV, or intraventricular heart block (except in patients with a functioning artificial pacemaker); premixed injection may contain corn-derived dextrose and its use is contraindicated in patients with allergy to corn or corn-related products.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional contraindications specific to spinal anesthesia include: Local infection at the site of proposed puncture, severe hemorrhage, shock, heart block, sepsis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to ester local anesthetics (paraben-containing solutions only); supraventricular arrhythmias; severe myocardial depression; antimicrobial preservative-containing solutions should not be used intra-or retro-ocularly or for epidural or spinal anesthesia or any route that would introduce solution into the cerebrospinal fluid or in doses ≥15 mL for other types of blockades.</p></div>
<div class="block war drugH1Div" id="F8768646"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is <b>not</b> an approved use; chondrolysis (primarily in the shoulder joint) has occurred following infusion, with some cases requiring arthroplasty or shoulder replacement.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants &lt;6 months are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic dysfunction: Use extreme caution in patients with severe hepatic dysfunction; may have increased risk of lidocaine toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Injectable anesthetic: Follow appropriate administration techniques so as not to administer any intravascularly. Solutions containing antimicrobial preservatives should not be used for epidural or spinal anesthesia. Some solutions contain a bisulfite; avoid in patients who are allergic to bisulfite. Resuscitative equipment, medicine and oxygen should be available in case of emergency. Adjust the dose for elderly, pediatric, acutely ill, and debilitated patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intravenous: Constant ECG monitoring is necessary during IV administration. Use cautiously in hepatic impairment, HF, marked hypoxia, severe respiratory depression, hypovolemia, history of malignant hyperthermia, or shock. Increased ventricular rate may be seen when administered to a patient with atrial fibrillation. Use is contraindicated in patients with Wolff-Parkinson-White syndrome and severe degrees of SA, AV, or intraventricular heart block (except in patients with a functioning artificial pacemaker). Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy. Correct any underlying causes of ventricular arrhythmias. Monitor closely for signs and symptoms of CNS toxicity. The elderly may be prone to increased CNS and cardiovascular side effects. Reduce dose in hepatic dysfunction and CHF.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CAST trial: In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, non-life-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide. An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. Antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.</p></div>
<div class="block foc drugH1Div" id="F8768838"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidomark 1/5: 1% [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidomark 2/5: 2% [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">P-Care X: 1% [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ReadySharp Lidocaine: 1% [DSC]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xylocaine: 0.5% (50 mL); 1% (20 mL, 50 mL); 2% (10 mL, 20 mL, 50 mL) [contains methylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5% (50 mL); 1% (2 mL, 5 mL, 10 mL, 20 mL, 50 mL); 2% (2 mL, 10 mL, 20 mL, 50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xylocaine-MPF: 0.5% (50 mL); 1% (2 mL, 5 mL, 10 mL, 30 mL); 1.5% (10 mL, 20 mL); 2% (2 mL, 5 mL, 10 mL) [methylparaben free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5% (50 mL); 1% (2 mL, 5 mL, 30 mL); 1.5% (20 mL); 2% (2 mL, 5 mL, 10 mL); 4% (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intraspinal, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Lidocaine 5% [50 mg/mL] and dextrose 7.5% (2 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.4% [4 mg/mL] (250 mL, 500 mL); 0.8% [8 mg/mL] (250 mL); 1% [10 mg/mL] (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/5 mL (5 mL); 100 mg/5 mL (5 mL)</p></div>
<div class="block geq drugH1Div" id="F8768599"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322268"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Lidocaine HCl (Cardiac) PF Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $0.83</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Lidocaine HCl (PF) Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $0.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per mL): $0.30 - $19.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5% (per mL): $0.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per mL): $0.27 - $0.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per mL): $1.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Lidocaine HCl Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $0.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per mL): $0.10 - $0.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per mL): $0.14 - $0.47</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Lidocaine in D5W Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/mL 5% (per mL): $0.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg/mL 5% (per mL): $0.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Xylocaine Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $0.13</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per mL): $0.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per mL): $0.23</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Xylocaine-MPF Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $0.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per mL): $0.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5% (per mL): $0.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per mL): $0.34</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Lidocaine HCl (Cardiac) Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/5 mL (per mL): $3.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $1.37 - $1.78</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Lidocaine HCl (Cardiac) PF Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/5 mL (per mL): $2.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $1.31</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869227"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xylocaine: 0.5% (20 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xylocaine: 1% (20 mL, 50 mL); 2% (20 mL, 50 mL) [contains methylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xylocaine Plain: 1% (2 mL, 5 mL, 10 mL); 2% (2 mL, 5 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (5 mL, 10 mL, 20 mL, 50 mL); 1% (2 mL, 5 mL, 20 mL, 50 mL); 2% (2 mL, 5 mL, 10 mL, 20 mL, 50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xylocard: 2% [20 mg/mL] (5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/5 mL (5 mL); 0.4% [4 mg/mL] (250 mL, 500 mL); 2% [20 mg/mL] (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/5 mL (5 mL)</p></div>
<div class="block adm drugH1Div" id="F8768797"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Bolus: According to the manufacturer, may administer at 25 to 50 mg/minute. In the setting of cardiac arrest (eg, ventricular fibrillation or pulseless ventricular tachycardia), may be infused rapidly into a peripheral vein (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11907287']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11907287'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous infusion: After initial bolus dosing, may administer as a continuous infusion; refer to indication-specific infusion rates in dosing for detailed recommendations. In the setting of cardiac arrest, infusion may be initiated once patient has return of spontaneous circulation resulting from lidocaine administration. Local thrombophlebitis may occur in patients receiving prolonged IV infusions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Infiltration or peripheral block:</b> Administer locally as single or multiple injections; may administer incremental injections or continuously through an indwelling catheter. Avoid rapid injection. Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intravesical (off-label use):</b> Various regimens of alkalinized lidocaine (with or without heparin) have been instilled into the bladder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19021619','lexi-content-ref-23432185','lexi-content-ref-22082303']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19021619','lexi-content-ref-23432185','lexi-content-ref-22082303'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">The On-Q® infusion pump is used to slowly administer local anesthetics (eg, bupivacaine, lidocaine, ropivacaine) to or around surgical wound sites and/or in close proximity to nerves for pre- or postoperative regional anesthesia. When infused directly into the shoulder, destruction of articular cartilage (chondrolysis) has occurred. On-Q® pumps should never be placed directly into any joint (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.1','lexi-content-ref-ISMP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.1','lexi-content-ref-ISMP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Endotracheal (off-label administration route):</b> Dilute in NS or sterile water. Absorption is greater with sterile water and results in less impairment of PaO<sub>2</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2240730']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2240730'])">Ref</a></span>). Stop compressions, spray drug quickly down tube. Flush with 5 mL of NS and follow immediately with several quick insufflations and continue chest compressions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Epidural and spinal anesthesia:</b> Do not use solutions containing preservatives. Do not puncture areas of the skin with signs of infection. Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraosseous (IO; off-label administration route):</b> Intraosseous administration is a reasonable alternative when quick IV access is not feasible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52614369"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Endotracheal: Infants, Children, and Adolescents: May administer dose undiluted <b>or</b> may further dilute in 1 to 5 mL NS based on patient size, followed by flush with ≥5 mL of NS after endotracheal administration; follow with 5 assisted manual ventilations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18245435','lexi-content-ref-31871244','lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18245435','lexi-content-ref-31871244','lexi-content-ref-20956230'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV push, Intraosseous: The manufacturer recommends that the rate of administration should not exceed 0.7 mg/kg/minute or 50 mg/minute, whichever is less; however, during acute situations (eg, pulseless ventricular tachycardia or ventricular fibrillation), administration by rapid IV push has been used by some clinicians in practice. Neonates: Loading doses for neonatal seizures are usually administered over 10 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31663153','lexi-content-ref-37655702']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31663153','lexi-content-ref-37655702'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Administer via an infusion pump.</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ/local infiltration: May use plain or buffered lidocaine; for circumcisions, use a 23- to 27-gauge needle for administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11177093','lexi-content-ref-10323627','lexi-content-ref-9417009','lexi-content-ref-3627593','lexi-content-ref-36474739','lexi-content-ref-24275281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11177093','lexi-content-ref-10323627','lexi-content-ref-9417009','lexi-content-ref-3627593','lexi-content-ref-36474739','lexi-content-ref-24275281'])">Ref</a></span>).</p></div>
<div class="block uica drugH1Div" id="F14472683"><span class="drugH1">Usual Infusion Concentrations: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premixed solutions available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> 1,000 mg in 250 mL (concentration: 4 mg/mL) <b>or</b> 2,000 mg in 250 mL (concentration: 8 mg/mL) of D<sub>5</sub>W.</p></div>
<div class="block uicp drugH1Div" id="F14472684"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premixed solutions available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> 4 mg/mL, 8 mg/mL.</p></div>
<div class="block use drugH1Div" id="F8768617"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Local or regional anesthesia: </b>Local and regional anesthesia by infiltration, nerve block, epidural, or spinal techniques.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular tachycardia, hemodynamically stable, sustained monomorphic:</b> Acute treatment of ventricular arrhythmias (eg, due to acute myocardial infarction [MI] or during cardiac manipulation [eg, cardiac surgery]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The routine prophylactic use of lidocaine to prevent arrhythmia associated during ST-elevation MI or to suppress isolated ventricular premature beats, couplets, runs of accelerated idioventricular rhythm, and nonsustained ventricular tachycardia is not recommended (ACCF/AHA [O'Gara 2013]).</p></div>
<div class="block off-label drugH1Div" id="F25726808"><span class="drugH1">Use: Off-Label: Adult</span><p>Interstitial cystitis (bladder pain syndrome); Intraosseous, infusion pain; Sudden cardiac arrest due to ventricular fibrillation or pulseless ventricular tachycardia (unresponsive to CPR, defibrillation, and epinephrine)</p></div>
<div class="block mst drugH1Div" id="F8768552"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration; IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lidosen [Italy] may be confused with Lincocin brand name for lincomycin [US, Canada, and multiple international markets]; Lodosyn brand name for carbidopa [US].</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F8768686"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (major), CYP2A6 (minor), CYP2B6 (minor), CYP2C9 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F8768687"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May increase the serum concentration of Lidocaine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Broccoli: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine: Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine.  Management: Avoid using any additional local anesthetics within 96 hours after insertion of the bupivacaine implant (Xaracoll) or bupivacaine and meloxicam periarticular solution (Zynrelef) or within 168 hours after subacromial infiltration (Posimir brand).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine (Liposomal): Lidocaine (Systemic) may enhance the adverse/toxic effect of BUPivacaine (Liposomal).  Management: Liposomal bupivacaine should not be administered with lidocaine. Liposomal bupivacaine may be administered 20 minutes or more after the administration of lidocaine. Lidocaine may be administered 96 hours or more after liposomal bupivacaine administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Lidocaine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inducers (Moderate): May decrease the serum concentration of Lidocaine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Strong): May increase the serum concentration of Lidocaine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Lidocaine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase serum concentrations of the active metabolite(s) of Lidocaine (Systemic). Specifically, concentrations of monoethylglycinexylidide (MEGX) may be increased. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lidocaine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Lidocaine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: May enhance the arrhythmogenic effect of Lidocaine (Systemic). Disopyramide may increase the serum concentration of Lidocaine (Systemic). Specifically, the unbound/free fraction of lidocaine may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: May decrease the serum concentration of Lidocaine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Lidocaine (Systemic) may enhance the adverse/toxic effect of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Topical): May enhance the adverse/toxic effect of Antiarrhythmic Agents (Class IB).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: May increase the serum concentration of Lidocaine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: May increase the serum concentration of Lidocaine (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of Lidocaine (Systemic).<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F8768621"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Lidocaine and its metabolites cross the placenta and can be detected in the fetal circulation following maternal injection for anesthesia prior to delivery (Cavalli 2004; Mitani 1987).</p>
<p style="text-indent:0em;margin-top:2em;">Adverse reactions in the fetus/neonate may affect the CNS, heart, or peripheral vascular tone. Fetal heart monitoring is recommended by the manufacturer.</p>
<p style="text-indent:0em;margin-top:2em;">Lidocaine injection is approved for obstetric analgesia (eg, prior to epidural or spinal anesthesia). Lidocaine administered by local infiltration is used to provide analgesia prior to episiotomy and during repair of obstetric lacerations (ACOG 209 2019). Administration by the perineal route may result in greater absorption than administration by the epidural route (Cavalli 2004). Cumulative exposure from all routes of administration should be considered. The ACOG recommends that pregnant women should not be denied medically necessary surgery regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 775 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Medications used for the treatment of cardiac arrest in pregnancy are the same as in the nonpregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (AHA [Jeejeebhoy 2015]).</p></div>
<div class="block brc drugH1Div" id="F8768644"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The relative infant dose (RID) of lidocaine is 4.9% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 183 mg for epidural anesthesia.</p>
<p style="text-indent:-2em;margin-left:2em;">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">The RID of lidocaine was calculated using a mean milk concentration of 0.86 mcg/mL, providing an estimated daily infant dose via breast milk of 129 mcg/kg/day. This milk concentration was obtained following maternal administration lidocaine via local regional anesthesia to 22 women undergoing cesarean delivery. Milk was sampled 2 hours after the injection. Breast milk concentrations of lidocaine decreased over 12 hours (Ortega 1999). Lidocaine metabolites have also been detected in breast milk (Giuliani 2001; Lebedevs 1993; Puente 2001). Lower concentrations of lidocaine have been reported in breast milk following dental procedures, infusion for arrhythmias, and liposuction (Dryden 2000; Giuliani 2001; Lebedevs 1993; Zeisler 1986). Oral bioavailability to the breastfeeding infant is expected to be low (Lebedevs 1993; Ortega 1999).</p>
<p style="text-indent:-2em;margin-left:2em;">Available guidelines consider lidocaine to be compatible with breastfeeding when used as an antiarrhythmic or local anesthetic (ABM [Reece-Stremtan 2017]; WHO 2002). Cumulative exposure from all routes of administration should be considered.</p></div>
<div class="block dic drugH1Div" id="F8768796"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Premixed injection may contain corn-derived dextrose and its use is contraindicated in patients with allergy to corn-related products.</p></div>
<div class="block mop drugH1Div" id="F15577078"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">LFTs, ECG; neurologic signs and symptoms of toxicity (eg, perioral tingling, tinnitus, light-headedness, restlessness); in patients requiring continuous infusions or therapy &gt;24 hours, lidocaine serum concentrations if available and clinically relevant; consult individual institutional policies and procedures.</p></div>
<div class="block rer drugH1Div" id="F8768709"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> These ranges act as a general guide only; the correlation between toxic symptoms and plasma lidocaine concentrations is not fully reliable. Vulnerable patients may experience toxicity at lower levels (Foo 2021; Samarin 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">Therapeutic: 1.5 to 5 mcg/mL (SI: 6 to 21 micromole/L).</p>
<p style="text-indent:-2em;margin-left:2em;">Toxicity more common: &gt;6 mcg/mL (SI: &gt;26 micromole/L).</p></div>
<div class="block pha drugH1Div" id="F8768707"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Class Ib antiarrhythmic; suppresses automaticity of conduction tissue, by increasing electrical stimulation threshold of ventricle, His-Purkinje system, and spontaneous depolarization of the ventricles during diastole by a direct action on the tissues; blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction</p></div>
<div class="block phk drugH1Div" id="F8768710"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Systemic administration: Single IV bolus dose: 45 to 90 seconds.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Systemic administration: Single IV bolus dose: 10 to 20 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Systemic administration: Single IV bolus dose: 0.8 to 2.8 L/kg (Berkenstadt 1999); alterable by many patient factors; decreased in heart failure and liver disease; crosses blood-brain barrier.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Dependent on drug concentration; fraction bound decreases with increasing concentration. At 1 to 4 mcg/mL, 60% to 80% bound to alpha<sub>1</sub> acid glycoprotein.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: 90% hepatic via CYP1A2 and CYP3A4; active metabolites monoethylglycinexylidide (MEGX) and glycinexylidide (GX) can accumulate and may cause CNS toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Systemic administration: Biphasic: Initial: ~8 minutes following single IV bolus (Burm 1988); Terminal: Infants, premature: 3.2 hours; Adults: 1.5 to 2 hours following single IV bolus (Burm 1988; manufacturer's labeling). Prolonged with continuous infusions &gt;24 hours, heart failure, liver disease, shock, severe renal impairment, neonatal therapeutic hypothermia (van den Broek 2013; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;10% as unchanged drug, ~90% as metabolites).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F13276704"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Xylocaine | Xylocard</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Xylocard</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Lignocaine | Xylocaine | Xylocard</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Lidocaine</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Lidocaine accord</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Lidocain</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Xylocaina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Li shu ka | Lidocaine | Lidocaine aerosol (ii)</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Farmacaina | Lidocaina | Roxicaina | Xylocaina</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lidocain Braun | Lidocain hcl B. Braun | Lidocard | Min-I-Jet Lidocain | Ryligency | Xylocain | Xylonor n</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Roxicaina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Xylocaine</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Lidocaine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Xilonibsa</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lidocard | Xylocain | Xylocard</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ryligency | Xylocard</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Lignocaine | Sure | Xylocard</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Xylocaine | Xylocard</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Lidocain</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Xylocard</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Stud 100</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Lidocaina abbott</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Avocaine</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Lidocaine | Olives | Olives k | Olives takata | Xylocaine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Xylocaine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Lidocaine HCL | Ryligency | Xylocard | Xylonor</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Lidocaine | Procomil | Xylocaine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Xylocard</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Xylocard</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Xylocaine | Xylocard</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lidokain sad | Lignocaine hydrochloride fresenius | Xylocard</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Xylocaine plain | Xylocard</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Lidocaina | Roxicaina | Xilonest s.p. | Xylocaina</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Xylocaine</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Lignocaine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Lidocain | Lignocainum | Xylocain</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Aspercreme with lidocaine | Lidocaine HCL | Xylocaine cardiac</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Lidocaina | Lidocaina braun | Lidoject | Xylocard</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Lidocaina veinfar</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Lignoc | Medocaine | Zylodine</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Lidocain</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Xylocaine | Xylocard</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Xylocain | Xylocard</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Xylocard</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Xylocain</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Xylocaine | Xylocard</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Lidocain | Lidocaine | Lignocaine | Xylocaine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Lidocain</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Xylo Efa Cardiolog</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Farmacaina</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AlBaqui.1">
<a name="AlBaqui.1"></a>Al Baqui SA, Khan TH, Mollah AH, et al. Comparative efficacy of phenytoin versus lidocaine in the management of intractable seizure in neonate. <i>J Dhaka Med Coll</i>. 2016;25(2):94-99. doi:10.3329/jdmc.v25l2.33973</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29084731">
<a name="29084731"></a>Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death [published correction appears in <i>Circulation</i>. 2018;138(13):e419-e420]. <i>Circulation</i>. 2018;138(13):e272-e391. doi: 10.1161/CIR.0000000000000549.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/29084731/pubmed" id="29084731" target="_blank">29084731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22926175">
<a name="22926175"></a>American Academy of Pediatrics (AAP) Task Force on Circumcision. Male circumcision. <i>Pediatrics</i>. 2012;130(3):e756-e785. doi:10.1542/peds.2012-1990<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/22926175/pubmed" id="22926175" target="_blank">22926175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30801474">
<a name="30801474"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 209: obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2019;133(3):e208-e225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/30801474/pubmed" id="30801474" target="_blank">30801474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30913200">
<a name="30913200"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 775: nonobstetric surgery during pregnancy. <i>Obstet Gynecol</i>. 2019;133(4):e285-e286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/30913200/pubmed" id="30913200" target="_blank">30913200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.2">
<a name="ASHP.2"></a>American Society of Health-System Pharmacists (ASHP). Adult continuous infusion standards. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Adult-Infusion-Standards.pdf. Published October 2023b. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated September 2023a. Accessed October 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11177093">
<a name="11177093"></a>Anand KJ; International Evidence-Based Group for Neonatal Pain. Consensus statement for the prevention and management of pain in the newborn. <i>Arch Pediatr Adolesc Med</i>. 2001;155(2):173-180. doi:10.1001/archpedi.155.2.173<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/11177093/pubmed" id="11177093" target="_blank">11177093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi: 10.1002/cpt.377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10051088">
<a name="10051088"></a>Berkenstadt H, Segal E, Mayan H, et al. The pharmacokinetics of morphine and lidocaine in critically ill patients. <i>Intensive Care Med.</i> 1999;25(1):110-112. doi:10.1007/s001340050796<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/10051088/pubmed" id="10051088" target="_blank">10051088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28082013">
<a name="28082013"></a>Bohnhorst B, Hartmann H, Lange M. Severe methemoglobinemia caused by continuous lidocaine infusion in a term neonate. <i>Eur J Paediatr Neurol</i>. 2017;21(3):576-579. doi:10.1016/j.ejpn.2016.12.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/28082013/pubmed" id="28082013" target="_blank">28082013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3342287">
<a name="3342287"></a>Burm AG, de Boer AG, van Kleef JW, et al. Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. <i>Biopharm Drug Dispos.</i> 1988;9(1):85-95. doi:10.1002/bod.2510090109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/3342287/pubmed" id="3342287" target="_blank">3342287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15365654">
<a name="15365654"></a>Cavalli Rde C, Lanchote VL, Duarte G, et al, "Pharmacokinetics and Transplacental Transfer of Lidocaine and its Metabolite For Perineal Analgesic Assistance to Pregnant Women," <i>Eur J Clin Pharmacol</i>, 2004, 60(8):569-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/15365654/pubmed" id="15365654" target="_blank">15365654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2827545">
<a name="2827545"></a>Christoph RA, Buchanan L, Begalla K, Schwartz S. Pain reduction in local anesthetic administration through pH buffering. <i>Ann Emerg Med</i>. 1988;17(2):117-120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/2827545/pubmed" id="2827545" target="_blank">2827545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26473000">
<a name="26473000"></a>de Caen AR, Berg MD, Chameides L, et al. Part 12: Pediatric Advanced Life Support: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2015;132(18 Suppl 2):S526-S542.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/26473000/pubmed" id="26473000" target="_blank">26473000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oliveira.1">
<a name="Oliveira.1"></a>de Oliveira Duque-Estrada E. The use of buffering solutions in the pediatrics local anesthesia to reduce the pain of minor procedures. <i>Biomed J Sci &amp; Tech Res</i>. 2018;2(1):2363-2364. doi:10.26717/BISTR.2018.02.000695</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11907287">
<a name="11907287"></a>Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. <i>N Engl J Med</i>. 2002; 346:884-890.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/11907287/pubmed" id="11907287" target="_blank">11907287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10839430">
<a name="10839430"></a>Dryden RM, Lo MW. Breast milk lidocaine levels in tumescent liposuction. <i>Plast Reconstr Surg</i>. 2000;105(6):2267-2268.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/10839430/pubmed" id="10839430" target="_blank">10839430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30571264">
<a name="30571264"></a>Duff JP, Topjian A, Berg MD, et al. 2018 American Heart Association focused update on pediatric advanced life support: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2018;138(23):e731-e739.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/30571264/pubmed" id="30571264" target="_blank">30571264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31663153">
<a name="31663153"></a>Favié LMA, Huitema ADR, van den Broek MPH, et al. Lidocaine as treatment for neonatal seizures: evaluation of previously developed population pharmacokinetic models and dosing regimen. <i>Br J Clin Pharmacol</i>. 2020;86(1):75-84. doi:10.1111/bcp.14136<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/31663153/pubmed" id="31663153" target="_blank">31663153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956217">
<a name="20956217"></a>Field JM, Hazinski MF, Sayre MR, et al, "Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care," <i>Circulation</i>, 2010, 122(18 Suppl 3):640-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/20956217/pubmed" id="20956217" target="_blank">20956217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33141959">
<a name="33141959"></a>Foo I, Macfarlane AJR, Srivastava D, et al. The use of intravenous lidocaine for postoperative pain and recovery: international consensus statement on efficacy and safety. <i>Anaesthesia</i>. 2021;76(2):238-250. doi:10.1111/anae.15270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/33141959/pubmed" id="33141959" target="_blank">33141959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11321382">
<a name="11321382"></a>Giuliani M, Grossi GB, Pileri M, Lajolo C, Casparrini G. Could local anesthesia while breast-feeding be harmful to infants? <i>J Pediatr Gastroenterol Nutr</i>. 2001;32(2):142-144.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/11321382/pubmed" id="11321382" target="_blank">11321382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goyal.1">
<a name="Goyal.1"></a>Goyal NK. Circumcision. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 113.4.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2240730">
<a name="2240730"></a>Hähnel JH, Lindner KH, Schürmann C, et al, "Plasma Lidocaine Levels and PaO<sub>2</sub> With Endobronchial Administration: Dilution With Normal Saline or Distilled Water?"<i> Ann Emerg Med</i>, 1990, 19(11):1314-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/2240730/pubmed" id="2240730" target="_blank">2240730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AUA.2014">
<a name="AUA.2014"></a>Hanno PM, Burks DA, Clemens JQ, et al; American Urological Association Education and Research Inc. American Urological Association guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Published 2011. Updated December 5, 2014. Accessed March 17, 2020. https://www.auanet.org/guidelines/interstitial-cystitis-(ic/bps)-guideline
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AUA.2022">
<a name="AUA.2022"></a>Hanno PM, Burks DA, Clemens Q, et al; American Urological Association. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. https://www.auanet.org/guidelines-and-quality/guidelines/diagnosis-and-treatment-interstitial-of-cystitis/bladder-pain-syndrome-(2022). Published 2011. Updated 2022. Accessed August 24, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hazinski.1">
<a name="Hazinski.1"></a>Hazinski MF, Samson R, Schexnayder S. <i>2010 Handbook of Emergency Cardiovascular Care for Healthcare Providers</i>. South Deerfield, MA: American Heart Association; 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18245435">
<a name="18245435"></a>Hegenbarth MA, American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/18245435/pubmed" id="18245435" target="_blank">18245435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19947861">
<a name="19947861"></a>Hartholt KA, van Lieshout EM, Thies WC, Patka P, Schipper IB. Intraosseous devices: a randomized controlled trial comparing three intraosseous devices. <i>Prehosp Emerg Ca</i>re. 2010;14(1):6-13. doi: 10.3109/10903120903349861.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/19947861/pubmed" id="19947861" target="_blank">19947861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33927155">
<a name="33927155"></a>Hockett D, Kress L, Mac Donald R, Krenzischek DA, Maheshwari A. Effectiveness of buffered lidocaine for local anesthesia during liver biopsy. <i>Gastroenterol Nurs</i>. 2021;44(3):172-176. doi:10.1097/SGA.0000000000000542<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/33927155/pubmed" id="33927155" target="_blank">33927155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10323627">
<a name="10323627"></a>Holliday MA, Pinckert TL, Kiernan SC, Kunos I, Angelus P, Keszler M. Dorsal penile nerve block vs topical placebo for circumcision in low-birth-weight neonates. <i>Arch Pediatr Adolesc Med</i>. 1999;153(5):476-480. doi:10.1001/archpedi.153.5.476<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/10323627/pubmed" id="10323627" target="_blank">10323627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practice (ISMP). Process for handling elastomeric pain relief balls (ON-Q PainBuster and others) requires safety improvements.<i> ISMP Medication Safety Alert</i>. Published July 16, 2009a. Accessed December 12, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.2">
<a name="ISMP.2"></a>Institute for Safe Medication Practice (ISMP). Survey on LASA drug name pairs: who knows what’s on your list and the best ways to prevent mix-ups? <i>ISMP Medication Safety Alert</i>. Published May 21, 2009b. Accessed December 12, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26443610">
<a name="26443610"></a>Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/26443610/pubmed" id="26443610" target="_blank">26443610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10318297">
<a name="10318297"></a>Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients. <i>J Pharm Technol</i>. 1989;5(3):101-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/10318297/pubmed" id="10318297" target="_blank">10318297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric advanced life support: 2010 American Heart Association Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>, 2010;122(18 Suppl 3):S876-S908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9417009">
<a name="9417009"></a>Lander J, Brady-Fryer B, Metcalfe JB, Nazarali S, Muttitt S. Comparison of ring block, dorsal penile nerve block, and topical anesthesia for neonatal circumcision: a randomized controlled trial. <i>JAMA</i>. 1997;278(24):2157-2162.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/9417009/pubmed" id="9417009" target="_blank">9417009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8408724">
<a name="8408724"></a>Lebedevs TH, Wojnar-Horton RE, Yapp P, et al, "Excretion of Lignocaine and its Metabolite Monoethylglycinexylidide in Breast Milk Following its Use in a Dental Procedure. A Case Report," <i>J Clin Periodontol</i>, 1993, 20(8):606-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/8408724/pubmed" id="8408724" target="_blank">8408724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lidocaine.1">
<a name="Lidocaine.1"></a>Lidocaine Ansyr Abboject syringe (lidocaine) injection, USP [prescribing information]. Lake Forest, IL: Hospira Inc; April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lidocaine.1">
<a name="Lidocaine.1"></a>Lidocaine hydrochloride and dextrose injection [prescribing information]. Lake Forest, IL: Hospira; January 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lidocaine.2">
<a name="Lidocaine.2"></a>Lidocaine in D<sub>5</sub>W (lidocaine systemic) [prescribing information]. Lake Forest, IL: Hospira, Inc; April 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lidocaine.3">
<a name="Lidocaine.3"></a>Lidocaine injection [prescribing information]. Lake Forest, IL: Hospira, Inc; April 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16691409">
<a name="16691409"></a>Malingré MM, Van Rooij LG, Rademaker CM, et al. Development of an optimal lidocaine infusion strategy for neonatal seizures. <i>Eur J Pediatr</i>. 2006;165(9):598-604.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/16691409/pubmed" id="16691409" target="_blank">16691409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3627593">
<a name="3627593"></a>Maxwell LG, Yaster M, Wetzel RC, Niebyl JR. Penile nerve block for newborn circumcision. <i>Obstet Gynecol</i>. 1987;70(3 Pt 1):415-419.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/3627593/pubmed" id="3627593" target="_blank">3627593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3297463">
<a name="3297463"></a>Mitani GM, Steinberg I, Lien EJ, et al, "The Pharmacokinetics of Antiarrhythmic Agents in Pregnancy and Lactation," <i>Clin Pharmacokinet</i>, 1987, 12(4):253-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/3297463/pubmed" id="3297463" target="_blank">3297463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20831923">
<a name="20831923"></a>Moore PA and Hersh EV, "Local Anesthetics: Pharmacology and Toxicity," <i>Dent Clin North Am</i>, 2010, 54(4):587-99.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/20831923/pubmed" id="20831923" target="_blank">20831923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25147175">
<a name="25147175"></a>Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. <i>Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/25147175/pubmed" id="25147175" target="_blank">25147175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21345096">
<a name="21345096"></a>Nagler J, Krauss B. Videos in clinical medicine. Intraosseous catheter placement in children. <i>N Engl J Med</i>. 2011;364(8):e14. doi: 10.1056/NEJMvcm0900916.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/21345096/pubmed" id="21345096" target="_blank">21345096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956224">
<a name="20956224"></a>Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation. </i>2010;122(18 Suppl 3):729-767.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/20956224/pubmed" id="20956224" target="_blank">20956224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19021619">
<a name="19021619"></a>Nickel JC, Moldwin R, Lee S, Davis EL, Henry RA, Wyllie MG. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. <i>BJU Int</i>. 2009;103(7):910-918.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/19021619/pubmed" id="19021619" target="_blank">19021619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23432185">
<a name="23432185"></a>Nomiya A, Naruse T, Niimi A, et al. On- and post-treatment symptom relief by repeated instillations of heparin and alkalized lidocaine in interstitial cystitis. <i>Int J Urol</i>. 2013;20(11):1118-1122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/23432185/pubmed" id="23432185" target="_blank">23432185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-e425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36474739">
<a name="36474739"></a>Ogundele IO, Nwokoro CC, Adedeji TA, et al. Comparison of dorsal penile nerve block alone and in combination with lidocaine-prilocaine cream in neonates undergoing circumcision: a randomized controlled study. <i>World J Pediatr Surg</i>. 2022;5(4):e000470. doi:10.1136/wjps-2022-000470<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/36474739/pubmed" id="36474739" target="_blank">36474739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32463643">
<a name="32463643"></a>Omole F, Smith W, Carter-Wicker K. Newborn circumcision techniques. <i>Am Fam Physician</i>. 2020;101(11):680-685.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/32463643/pubmed" id="32463643" target="_blank">32463643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10225071">
<a name="10225071"></a>Ortega D, Viviand X, Lorec AM, et al, "Excretion of Lidocaine and Bupivacaine in Breast Milk Following Epidural Anesthesia For Cesarean Delivery," <i>Acta Anaesthesiol Scand</i>, 1999, 43(4):394-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/10225071/pubmed" id="10225071" target="_blank">10225071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081529">
<a name="33081529"></a>Panchal AR, Bartos JA, Cabañas JG, et al; Adult Basic and Advanced Life Support Writing Group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16 suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/33081529/pubmed" id="33081529" target="_blank">33081529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22082303">
<a name="22082303"></a>Parsons CL, Zupkas P, Proctor J, et al. Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis. <i>J Sex Med</i>. 2012;9(1):207-212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/22082303/pubmed" id="22082303" target="_blank">22082303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22478919">
<a name="22478919"></a>Pascuet E, Donnelly RF, Garceau D, Vaillancourt R. Buffered lidocaine hydrochloride solution with and without epinephrine: stability in polypropylene syringes. <i>Can J Hosp Pharm</i>. 2009;62(5):375-380. doi:10.4212/cjhp.v62i5.824<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/22478919/pubmed" id="22478919" target="_blank">22478919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20124120">
<a name="20124120"></a>Peberdy MA, Callaway CW, Neumar RW, et al. Part 9: Post Cardiac Arrest Care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18) (suppl 3):768-786.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/20124120/pubmed" id="20124120" target="_blank">20124120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20868946">
<a name="20868946"></a>Philbeck TE, Miller LJ, Montez D, Puga T. Hurts so good. Easing IO pain and pressure. <i>JEMS</i>. 2010;35(9):58-62, 65-6, 68; quiz 69. doi:10.1016/S0197-2510(10)70232-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/20868946/pubmed" id="20868946" target="_blank">20868946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22058104">
<a name="22058104"></a>Phillips MS, "Standardizing I.V. Infusion Concentrations: National Survey Results," <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/22058104/pubmed" id="22058104" target="_blank">22058104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37655702">
<a name="37655702"></a>Pressler RM, Abend NS, Auvin S, et al. Treatment of seizures in the neonate: guidelines and consensus-based recommendations-special report from the ILAE Task Force on Neonatal Seizures. <i>Epilepsia</i>. 2023;64(10):2550-2570. doi:10.1111/epi.17745<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/37655702/pubmed" id="37655702" target="_blank">37655702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11765029">
<a name="11765029"></a>Puente NW, Josephy PD. Analysis of the lidocaine metabolite 2,6-dimethylaniline in bovine and human milk.<i> J Anal Toxicol</i>. 2001;25(8):711-715.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/11765029/pubmed" id="11765029" target="_blank">11765029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; The Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017.<i> Breastfeed Med</i>. 2017;12(9):500-506. doi: 10.1089/bfm.2017.29054.srt.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24275281">
<a name="24275281"></a>Roman-Rodriguez CF, Toussaint T, Sherlock DJ, Fogel J, Hsu CD. Pre-emptive penile ring block with sucrose analgesia reduces pain response to neonatal circumcision. <i>Urology</i>. 2014;83(4):893-898. doi:10.1016/j.urology.2013.10.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/24275281/pubmed" id="24275281" target="_blank">24275281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32748017">
<a name="32748017"></a>Rossi S, Buonocore G, Bellieni CV. Management of pain in newborn circumcision: a systematic review. <i>Eur J Pediatr</i>. 2021;180(1):13-20. doi:10.1007/s00431-020-03758-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/32748017/pubmed" id="32748017" target="_blank">32748017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26335213">
<a name="26335213"></a>Samarin MJ, Mohrien KM, Oliphant CS. Continuous intravenous antiarrhythmic agents in the intensive care unit: strategies for safe and effective use of amiodarone, lidocaine, and procainamide. <i>Crit Care Nurs Q</i>. 2015;38(4):329-344. doi:10.1097/CNQ.0000000000000082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/26335213/pubmed" id="26335213" target="_blank">26335213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22029625">
<a name="22029625"></a>Schalk R, Schweigkofler U, Lotz G, Zacharowski K, Latasch L, Byhahn C. Efficacy of the EZ-IO needle driver for out-of-hospital intraosseous access--a preliminary, observational, multicenter study. <i>Scand J Trauma Resusc Emerg Med</i>. 2011;19:65. doi:10.1186/1757-7241-19-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/22029625/pubmed" id="22029625" target="_blank">22029625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29150457">
<a name="29150457"></a>Sharara-Chami R, Lakissian Z, Charafeddine L, Milad N, El-Hout Y. Combination analgesia for neonatal circumcision: a randomized controlled trial. <i>Pediatrics</i>. 2017;140(6):e20171935. doi:10.1542/peds.2017-1935<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/29150457/pubmed" id="29150457" target="_blank">29150457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081526">
<a name="33081526"></a>Topjian AA, Raymond TT, Atkins D, et al. Part 4: Pediatric basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16 Suppl 2):S469-S523. doi:10.1161/CIR.0000000000000901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/33081526/pubmed" id="33081526" target="_blank">33081526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21651313">
<a name="21651313"></a>van den Broek MP, Huitema AD, van Hasselt JG, et al. Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizures. <i>Clin Pharmacokinet</i>. 2011;50(7):461-469.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/21651313/pubmed" id="21651313" target="_blank">21651313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23303304">
<a name="23303304"></a>van den Broek MP, Rademaker CM, van Straaten HL, et al. Anticonvulsant treatment of asphyxiated newborns under hypothermia with lidocaine: efficacy, safety and dosing. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2013;98(4):F341-345.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/23303304/pubmed" id="23303304" target="_blank">23303304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956228">
<a name="20956228"></a>Vanden Hoek TL, Morrison LJ, Shuster M, et al, “Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” <i>Circulation</i>, 2010, 122(18 Suppl 3):829-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/20956228/pubmed" id="20956228" target="_blank">20956228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26719344">
<a name="26719344"></a>Weeke LC, Toet MC, van Rooij LG, et al. Lidocaine response rate in a EEG-confirmed neonatal seizures: Retrospective study of 413 full-term and preterm infants. <i>Epilepsia</i>. 2016;57(2):233-242.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/26719344/pubmed" id="26719344" target="_blank">26719344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xylocaine.1">
<a name="Xylocaine.1"></a>Xylocaine (lidocaine) [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xylocaine.2">
<a name="Xylocaine.2"></a>Xylocaine injection for ventricular arrhythmias (lidocaine systemic) [prescribing information]. Schaumburg, IL: APP Pharmaceuticals LLC; May 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xylocaine.3">
<a name="Xylocaine.3"></a>Xylocard (lidocaine solution, IV) [product monograph]. Oakville, Ontario, Canada: Aspen Pharmacare Canada Inc; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3757781">
<a name="3757781"></a>Zeisler JA, Gaarder TD, De Mesquita SA. Lidocaine excretion in breast milk. <i>Drug Intell Clin Pharm</i>. 1986;20(9):691-693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-local-and-regional-anesthetic-and-systemic-drug-information/abstract-text/3757781/pubmed" id="3757781" target="_blank">3757781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zipes.1">
<a name="Zipes.1"></a>Zipes DP and Jalife J, "Lidocaine," <i>Cardiac Electrophysiology: From Cell to Bedside</i>, 3rd ed, Philadelphia, PA: WB Saunders Co, 2000, 896.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10274 Version 504.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
